神经母细胞瘤免疫疗法的研究进展
RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.
作者信息
Booker Latania Y, Ishola Titilope A, Bowen Kanika A, Chung Dai H
机构信息
Department of Surgery The University of Texas Medical Branch Galveston, TX 77555.
出版信息
Curr Pediatr Rev. 2009 May;5(2):112-117. doi: 10.2174/157339609788185686.
Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of pediatric cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.
神经母细胞瘤是美国第三常见的儿童癌症，占儿童癌症相关死亡人数的15%。尽管多模式治疗取得了重大进展，但仍有若干患者的临床结局较差。由于迫切需要在神经母细胞瘤的治疗和管理方面进行创新并提高成功率，近年来对免疫疗法的研究兴趣不断增加。目前正在研究的免疫治疗方法包括靶向神经母细胞瘤抗原GD2的抗体、免疫细胞的细胞因子刺激、免疫细胞因子缀合物的使用、放射免疫疗法以及肿瘤致敏树突状细胞。免疫疗法可以作为当前治疗方案的安全替代或辅助方法，并且推测可能具有较少的有害影响，对患者更有利。
Zotero 插件